Fig. 2: Expressions of CD39, CD73, and CD26 on various types of ATLL cells, and the correlation of CD39 expression with prognosis. | Leukemia

Fig. 2: Expressions of CD39, CD73, and CD26 on various types of ATLL cells, and the correlation of CD39 expression with prognosis.

From: Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function

Fig. 2

a–c Plot of the mean fluorescence intensities (MFIs) of CD39, CD73, and CD26 on the cells in fraction P (CADM1−CD7+) and fraction N (CADM1+CD7−). Horizontal bars indicate median values. CD39 and CD26: P < 0.001, and CD73: P < 0.01. d, e Frequencies of CD39+ and CD73+ cells among CD4+ T cells within fraction N (CADM1+CD7−) from patients with acute/lymphoma, chronic/smordering subtypes of ATLL or HTLV-1 carrier. f Transformation-free survival of chronic/smoldering patients stratified by CD39 expression leukemic cells. Patients with chronic (n = 12) and smoldering (n = 2) ATLL were followed after blood collection up to a maximum of 2 years. Solid line indicates CD39+ patients, and dotted line indicates CD39−.

Back to article page